Fatty Liver Studies

HAVE YOU BEEN STRUGGLING TO IMPROVE YOUR LIVER HEALTH?

Find out more about SYNCHRONY Histology, a clinical trial of an investigational drug for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH)

If you have NASH/MASH (a type of NAFLD/MASLD) and were told you have liver fibrosis (scarring), you may be able to join the SYNCHRONY Histology study of an investigational drug called efruxifermin (EFX), taken as a self-administered weekly injection. Histology is the study of tissue—in this case, liver tissue—under a microscope. You will be provided usual standard of care (exercise and dietary counseling) in addition to the study medication. The aim of this 5-year-long study is to find out more about how safe and effective EFX may be in adults with NASH/MASH. Participation in this clinical trial includes data privacy and identity protection for all those participating.

Diversity in the SYNCHRONY Histology study

Clinical trials encourage everyone with the disease (or that suspect they have the disease) to participate to advance treatment for everyone with NAFLD/MASLD.
You may be able to join if you:

Are 18 to 80 years old
Have had a liver biopsy that showed NASH/MASH or are willing to undergo a biopsy
Have or ever had type 2 diabetes or 2 out of 4 signs of metabolic syndrome (overweight, have high cholesterol, elevated blood pressure, and/or elevated fasting blood glucose)
Have a body mass index (BMI) ≥ 25.0kg/m2

Travel reimbursement and travel support for participants may be offered throughout the study. Ask your study team for more information.

Get Started Now!

Don't Worry! You are not committed to participate in a study by completing this form.

By hitting "Submit" button you consent us to send you SMS updates. Frequency may vary. Message & data rates may apply. Reply STOP to opt out or HELP for more information. View our terms and privacy policy at our website

Seela Ramesh, MD

Dr. Ramesh is a board-certified Gastroenterologist with extensive expertise in Advanced and Therapeutic Endoscopy, ERCP, Endoscopic Ultrasonography (EUS), and the management of liver diseases. He completed his medical education at the Medical College of Virginia, an institution globally recognized for its excellence in Gastroenterology and Hepatology.

A highly experienced Principal Investigator, Dr. Ramesh has led numerous clinical trials across a wide range of therapeutic areas, including hepatology, inflammatory bowel disease (IBD), and metabolic liver disorders. His research contributions have helped advance innovative treatments, and he has been published in leading peer-reviewed journals. His work includes studies on hepatitis C, nonalcoholic fatty liver disease (NAFLD), and the role of cannabinoid receptors in hepatic metabolism.

Dr. Ramesh’s publications and presentations include:

Ramesh, S., & Sanyal, A. J. (2004). Hepatitis C and nonalcoholic fatty liver disease. Seminars in Liver Disease, 24(4), 399-413.
Ramesh, S., & Sanyal, A. J. (2005). Evaluation and management of non-alcoholic steatohepatitis. Journal of Hepatology, 42(1), S2-S12.
Ramesh, S., Mirashi, F., Choudhoury, J., & Sanyal, A. J. (2005). Cannabinoids block interferon-mediated suppression of hepatitis C virus replicon. AASLD, Poster Presentation.
Ramesh, S., Mirashi, F., Choudhoury, J., Gupta, S., & Sanyal, A. J. (2005). Methanandamide promotes hepatic lipogenesis by increasing SREBP-1 and SREBP-2 activity—a novel effect of cannabinoid (CB1) receptor activation. AASLD, Poster Presentation.
Qasem, A., Ramesh, S., & Naser, S. A. (2018). Role of TNF antagonists in susceptibility to mycobacterial infection in association with genetic polymorphisms in Crohn's disease. UCD Biomedical Sciences Annual Graduate Research Symposium, Poster Presentation.

Dr. Ramesh is a Clinical Assistant Professor of Medicine at the University of Central Florida and plays an active role in training medical professionals at Osceola Regional Medical Center. He is also a distinguished member of professional organizations, including the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), the American Association for the Study of Liver Diseases (AASLD), and the Crohn’s & Colitis Foundation (CCF).

With a strong background in clinical research, protocol development, and investigational therapies, Dr. Ramesh is dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials.